Covidien And BioSynthema Sign Exclusive Agreements For Neuroendocrine Cancer Therapy Technology

Posted by Patrick McDowell in Health News | Comments Off

Covidien Ltd. (NYSE:COV) (BSX:COV) and BioSynthema Inc. yesterday announced the signing of agreements to develop and commercialize a nuclear medicine therapy for neuroendocrine cancer patients. Under the terms of an exclusive license agreement, BioSynthema will gain access to specific Covidien proprietary peptide technology. [click link for full article]